Success Metrics

Clinical Success Rate
33.3%

Based on 2 completed trials

Completion Rate
33%(2/6)
Active Trials
1(11%)
Results Posted
50%(1 trials)
Terminated
4(44%)

Phase Distribution

Ph phase_3
2
22%
Ph phase_2
3
33%
Ph phase_1
3
33%

Phase Distribution

3

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

28.6%

2 of 7 finished

Non-Completion Rate

71.4%

5 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(2)
Terminated(5)

Detailed Status

Terminated4
Completed2
Recruiting1
Withdrawn1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 23 (37.5%)
Phase 32 (25.0%)

Trials by Status

recruiting111%
withdrawn111%
completed222%
not_yet_recruiting111%
terminated444%

Recent Activity

1 active trials
Showing 5 of 9
recruiting

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

NCT07147101
withdrawnphase_2

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

NCT06308575
terminatedphase_2

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

NCT04119453
terminatedphase_1

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

NCT04073615
not_yet_recruitingphase_2

Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor

NCT06200233
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07147101

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Recruiting
NCT06308575Phase 2

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Withdrawn
NCT04119453Phase 2

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Terminated
NCT04073615Phase 1

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

Terminated
NCT06200233Phase 2

Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor

Not Yet Recruiting
NCT04985136Phase 3

A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

Terminated
NCT03042611Phase 3

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

Completed
NCT05287360Phase 1

A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants

Completed
NCT03707028Phase 1

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

Terminated

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9